Prosperity Wealth Management Inc. Invests $54,000 in Anixa Biosciences, Inc. (NASDAQ:ANIX)

Prosperity Wealth Management Inc. purchased a new position in shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 23,100 shares of the company’s stock, valued at approximately $54,000.

Separately, Virtu Financial LLC acquired a new position in shares of Anixa Biosciences during the third quarter worth $34,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ANIX shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday, February 18th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

Anixa Biosciences Price Performance

NASDAQ ANIX opened at $2.68 on Thursday. The stock’s fifty day moving average price is $2.79 and its 200 day moving average price is $3.02. Anixa Biosciences, Inc. has a 1 year low of $2.07 and a 1 year high of $4.20. The company has a market cap of $86.29 million, a price-to-earnings ratio of -6.87 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Tuesday, March 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Research analysts expect that Anixa Biosciences, Inc. will post -0.41 earnings per share for the current year.

Insider Activity at Anixa Biosciences

In related news, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the business’s stock in a transaction on Friday, January 17th. The shares were bought at an average cost of $2.57 per share, with a total value of $25,700.00. Following the transaction, the director now owns 922,334 shares of the company’s stock, valued at approximately $2,370,398.38. This trade represents a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Amit Kumar purchased 43,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were bought at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the transaction, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 75,289 shares of company stock valued at $177,021 in the last ninety days. Company insiders own 25.30% of the company’s stock.

Anixa Biosciences Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.